Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.48 |
| ▸ | KDM1B | Q8NB78 | 3/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29666934 | 1.00 | KDM1A (0.48) | KDM1AKCNH2KDM1BCYP2A6HSP90AA1 | |
| SCHEMBL29544666 | 0.87 | KDM1A (0.41) | KDM1AKCNH2KDM1B | |
| SCHEMBL577838 | 0.87 | KDM1A (0.41) | KDM1AKCNH2KDM1B | |
| SCHEMBL21617924 | 0.82 | KDM1A (0.38) | KDM1AKCNH2KDM1B | |
| SCHEMBL2487490 | 0.82 | KDM1A (0.39) | KDM1AKCNH2KDM1B | |
| SCHEMBL441345 | 0.82 | KDM1A (0.43) | KDM1AKCNH2KDM1B | |
| SCHEMBL2014602 | 0.82 | KDM1A (0.39) | KDM1AKCNH2KDM1B | |
| SCHEMBL10301570 | 0.82 | KDM1A (0.39) | KDM1AKCNH2KDM1B | |
| SCHEMBL258026 | 0.82 | ALOX15 (0.40) | KDM1AKCNH2KDM1B | |
| SCHEMBL31342136 | 0.82 | KDM1A (0.39) | KDM1AKCNH2KDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117924237-A | ((2, 3-Diamino-5, 6-difluoro-1, 4-phenyl) bis (thiophene-5, 2-diyl)) bis (2-cyanoacrylate) and preparation method and application thereof | 湘潭大学 | 2024-04-26 | — | — | CN | claimed |
| CN-113042011-B | Application of fluorine-containing conjugated microporous polymer | 南昌航空大学 | 2022-07-12 | — | — | CN | claimed |
| CN-113683601-A | Diaza-benzo-fluoranthene compound and preparation method and application thereof | 广东工业大学 | 2021-11-23 | — | — | CN | claimed |
| CN-113042011-A | Fluorine-containing conjugated microporous polymer and preparation method and application thereof | 南昌航空大学 | 2021-06-29 | — | — | CN | claimed |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12617798-B2 | Imidazopyrazne derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12600698-B2 | Kinase inhibitors | VIDYA THERAPEUTICS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4698516-A1 | PYRROLIDINONE UREA FPR2 AGONISTS | Bristol-Myers Squibb Company (US) | 2026-02-25 | — | — | EP | disclosed |
| EP-4698275-A1 | PYRROLIDINONE UREA FPR2 AGONISTS | Bristol-Myers Squibb Company (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-3941919-B1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. | GENENTECH INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250353862-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2025-11-20 | — | — | US | disclosed |
| US-6433231-B2 | BROMINATION THE CORRESPONDING NAPHTHALENE HALOGEN COMPOUND | NIPPON SHOKUBAI CO., LTD. (JP) | 2002-08-13 | — | — | US | disclosed |
| US-20010045350-A1 | Method for production of halogen-containing aromatic compound | NIPPON SHOKUBAI CO., LTD., A JAPAN CORPORATION | 2001-11-29 | — | — | US | disclosed |
| JP-2001247501-A | AROMATIC COMPOUND AND METHOD OF PRODUCING THE SAME | NIPPON SHOKUBAI CO LTD | 2001-09-11 | — | — | JP | disclosed |
| US-6288290-B1 | BROMINATION AND PHOTOBROMINATION OF AROMATIC COMPOUNDS | NIPPON SHOKUBAI, CO., LTD. (JP) | 2001-09-11 | — | — | US | disclosed |
| EP-0995734-A1 | Method for production of halogen-containing aromatic compound | Nippon Shokubai Co., Ltd. (JP) | 2000-04-26 | — | — | EP | disclosed |
| EP-0578054-B1 | Meta-substituted six membered aromatic rings for use in liquid crystal mixtures | HOECHST AG (DE) | 1999-05-19 | — | — | EP | disclosed |
| US-5447656-A | Meta-substituted aromatic compounds having six-membered rings, for use in liquid-crystal mixtures | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-09-05 | — | — | US | disclosed |
| EP-0578054-A1 | Meta-substituted six membered aromatic rings for use in liquid crystal mixtures | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | KDM1A 1642/4885KCNH2 4066/4885KDM1B 982/4885 |
| US-12600698-B2 | Kinase inhibitors | BTK, BMX, GSK3B | KDM1A 2098/4885KCNH2 1794/4885KDM1B 2642/4885 |
| US-20010045350-A1 | Method for production of halogen-containing aromatic compound | CBR1, CBR3, DCXR | KDM1A 1663/4885KCNH2 20/4885KDM1B 1115/4885 |
| US-20250353862-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | KDM1A 3210/4885KCNH2 4582/4885KDM1B 2718/4885 |
| US-12617798-B2 | Imidazopyrazne derivatives | CLIC1, HCFC1, CXCR1 | KDM1A 1299/4885KCNH2 113/4885KDM1B 2226/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | KDM1A 470/4885KCNH2 4049/4885KDM1B 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.